1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Humacyte received a Nasdaq notice that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days ended July 30, 2026. The company has 180 calendar days, until January 27, 2027, to regain compliance, which requires a closing bid of $1.00 or more for at least 10 consecutive business days. Nasdaq says the notice has no immediate effect on the stock's listing, but the company cannot assure it will regain compliance.
Notice received July 31, 2026, for 30 consecutive business days ended July 30, 2026 below $1.00 bid price
Compliance period runs until January 27, 2027 (180 calendar days)
Regaining compliance requires closing bid of $1.00 or more for at least 10 consecutive business days
Stock continues to trade on The Nasdaq Global Select Market under HUMA
A Seoul court ruled against Franklin Technology, a South Korean subsidiary of Franklin Wireless, in a commercial contract dispute with Partron Co. The company is reviewing the decision and evaluating options, including an appeal, and says it intends to vigorously defend its position.
Court ruling issued July 28, 2026 by the Seoul Central District Court (62nd Civil Division)
Damages of approximately $3,673,336 plus 5% annual interest from November 4, 2022 through July 16, 2026
Post-judgment interest of 12% per annum applies from July 17, 2026 until full payment
The dispute relates to a commercial contract for development and production of devices
Traws Pharma received a Nasdaq notice on July 29, 2026 that its common stock has traded below $1.00 per share for at least 30 consecutive business days, so it is not currently meeting the minimum bid price requirement. The notice has no immediate effect on the listing, but the company has until January 25, 2027 to regain compliance, and it could face delisting if it does not.
Nasdaq notice received July 29, 2026 under Listing Rule 5550(a)(2)
Closing bid price was below $1.00 for at least 30 consecutive business days
Compliance period runs until January 25, 2027; regaining compliance requires at least 10 consecutive business days at or above $1.00
A second 180-day grace period may be available if the company meets listing standards and gives notice of intent to cure
GD Culture Group received written notice from Nasdaq on July 29, 2026 that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, and that the matter is now closed. The notice removes the bid price deficiency as an open listing issue for the company's shares.
Nasdaq notice dated July 29, 2026 confirms regained compliance with the $1.00 minimum bid price requirement
Compliance is under Nasdaq Listing Rule 5550(a)(2); Nasdaq states the matter is now closed
Filing also incorporates this report into the company's Form S-3 registration statement (File No. 333-292934)
Context Therapeutics received a Nasdaq notice on July 29, 2026 stating its common stock failed to maintain a $1.00 minimum closing bid price for 30 consecutive business days. The company has until January 25, 2027 to regain compliance, and the notice has no immediate effect on its listing or trading, but failure to regain compliance could lead to delisting proceedings.
Nasdaq notice dated July 29, 2026 cites Listing Rule 5550(a)(2), the minimum bid price rule
Compliance deadline is January 25, 2027, after a 180 calendar day initial period
Company may be eligible for an additional 180-day Second Compliance Period if it meets listing requirements and notifies Nasdaq of its intent to cure
The notice has no immediate effect on the company's listing or trading
DocGo received a Nasdaq letter on July 28, 2026, granting an additional 180 calendar days, until January 25, 2027, to regain compliance with the minimum bid price requirement. The company's stock must close at or above $1.00 for at least 10 consecutive business days to regain compliance, and the company says it cannot assure it will do so in time. Shareholders should note that the company may pursue a reverse stock split, which stockholders approved at the June 16, 2026 annual meeting.
Nasdaq granted an additional 180 calendar days, until January 25, 2027, to meet the $1.00 minimum bid price requirement
Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
Stockholders approved a reverse stock split at ratios of 1-for-5 to 1-for-10 at the June 16, 2026 annual meeting, with the final ratio to be set by the Board
ImmunityBio announced on July 29, 2026 that the UAE's Emirates Drug Establishment granted marketing authorization for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer and in metastatic non-small cell lung cancer after checkpoint inhibitor failure. The filing says this brings ANKTIVA's regulatory footprint to 34 countries, but it contains no revenue, sales, or financial results, so the direct financial effect on shareholders is not quantified.
UAE authorization granted with first registration in July 2026 and validity through July 2031.
Bladder cancer indication (with BCG) covers CIS with or without papillary tumors, described as the first worldwide to span the full spectrum of BCG-unresponsive disease.
Lung cancer indication (with checkpoint inhibitors) covers metastatic NSCLC after progression; median overall survival was 14.6 months in the 79-patient QUILT-3.055 study.
ImmunityBio's regional partner in the UAE is Modern Pharmaceutical Company.
AnaptysBio disclosed that the Court granted a joint stipulation setting the post-trial briefing schedule in its consolidated litigation with Tesaro and GlaxoSmithKline, following a trial held July 14-17, 2026. The filing contains no ruling on the merits, so the outcome of the dispute remains unresolved for shareholders.
Trial of the consolidated Tesaro litigation was held July 14-17, 2026.
The Court granted the parties' Joint Stipulation on July 28, 2026.
AnaptysBio's opening post-trial brief is due August 21, 2026, and post-trial argument is set for October 20, 2026.
An FDA advisory committee voted on July 29, 2026 that available evidence did not support the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy patients. The vote is non-binding, and the FDA will consider it in its ongoing review of the Biologics License Application, whose PDUFA target action date remains August 22, 2026.
Committee vote on July 29, 2026 was 3 for, 9 against and 0 abstaining
The Committee's recommendation is non-binding; the FDA will weigh it with the full administrative record
PDUFA target action date for the BLA remains August 22, 2026
In a separate upper limb function discussion, the Committee's feedback was directionally supportive of Phase 3 HOPE-3 data, including the PUL 2.0 primary endpoint
Curis received written notice from Nasdaq on July 24, 2026 that it has regained compliance with the bid price rule and is in full compliance with the Nasdaq Hearings Panel's terms. The company will be subject to a one-year Discretionary Panel Monitor from July 24, 2026, meaning any new continued listing deficiency would lead to a delist determination and a hearing without additional time to cure, and there is no assurance it will remain listed.
Nasdaq notice dated July 24, 2026 confirms regained compliance with Listing Rule 5550(a)(2), the bid price rule
Discretionary Panel Monitor applies for one year from July 24, 2026 under Listing Rule 5815(d)(4)(A)
Any new continued listing deficiency during the monitor period gets no plan of compliance or extra time to cure
Filing states there can be no assurance Curis will remain listed on Nasdaq
Xencor entered a settlement agreement with Alexion that resolves a dispute over U.S. royalties on Ultomiris, with Xencor to receive $105 million in two equal payments. Alexion will have no further obligation to pay royalties on U.S. sales, while ex-U.S. royalties are unchanged. Xencor said that, based on current operating plans, it expects cash to fund research and development programs and operations through 2028.
Total payment of $105 million, in two $52.5 million installments
First $52.5 million payment anticipated in August 2026; second payment due within 14 days after the one-year anniversary of the agreement
Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris; ex-U.S. royalties are unchanged
Cash runway expected through 2028; year-end 2026 cash guidance to be updated with second-quarter 2026 results
Foxx Development Holdings received a Nasdaq deficiency letter on July 22, 2026, saying its market value of listed securities closed below the $35 million continued-listing threshold for 30 consecutive business days. The company has until January 19, 2027 to regain compliance, which requires closing at $35 million or more for at least ten consecutive business days; failing that, it faces a delisting determination that it could appeal.
Nasdaq letter dated July 22, 2026 cites MVLS below the $35,000,000 threshold for 30 consecutive business days
Compliance deadline is January 19, 2027 under Nasdaq Listing Rule 5810(c)(3)(C)
Regaining compliance requires MVLS of $35 million or more for at least ten consecutive business days
Company says it may consider options to regain compliance but gives no assurance it will succeed
NeuroPace received an FDA communication that its Premarket Approval Supplement to expand the RNS System indication to drug-resistant idiopathic generalized epilepsy is not approvable as submitted, and FDA has requested additional clinical evidence. The company says it will file a Submission Issue Request and amend the submission, and that its guidance does not include any contribution from the expanded indication.
FDA communication was received on the PMA-S target due date, and the company says it has begun working with FDA on the review team and a subsequent SIR meeting.
FDA requested additional clinical evidence from the NAUTILUS trial and literature supporting the submission.
At 18 months, patients treated with the RNS System had a 77% median reduction in GTC seizures from baseline, and 40% achieved GTC seizure freedom.
Full second quarter 2026 results and any full year outlook updates are scheduled for the August 11, 2026 earnings call.
Grace Therapeutics announced it received the FDA's official minutes from a Type A meeting on the April 23, 2026 Complete Response Letter for GTx-104. The company says the FDA cited facility-level cGMP issues at its contract manufacturer and additional leachables and excipient data, and it is adding a second, U.S.-based contract manufacturer as a backup route to resubmission. The filing gives no resubmission date, so the timing of a possible approval remains open.
FDA Type A meeting minutes received; CRL issued April 23, 2026 for GTx-104 new drug application
FDA did not identify clinical safety or efficacy deficiencies and did not request additional clinical data
Company is pursuing a dual-source manufacturing strategy with a second U.S.-based contract manufacturer; no single resubmission path has been designated
Corporate presentation updated July 28, 2026 to reflect the path to NDA resubmission
Johnson & Johnson said it reached an agreement to comprehensively resolve the remaining ovarian talc litigation, covering about 76,000 claims, with a $5.5 billion commitment by the company. The deal is conditioned on participation by at least 95% of the remaining claims, and the company said it continues to deny that its talc products cause cancer.
Company commitment of $5.5 billion, with the first payment of no more than $3 billion due in 2027 and no additional payments due before 2028
Agreement conditioned on participation of at least 95% of the remaining claims, including lead plaintiff firms in federal MDL and state court cases
Announced July 27, 2026, following a July 22, 2026 MDL court order requiring plaintiffs to show why remaining claims should not be dismissed
An arbitrator dismissed SELLAS's claims against licensee 3D Medicines on July 24, 2026, and allocated about $1.0 million of 3D Medicines' legal fees and costs to be paid by SELLAS. The filing also gives unaudited cash and cash equivalents of $138.3 million as of June 30, 2026, which may differ materially from the figures in the company's final financial statements. The dismissal removes SELLAS's claims over $13.0 million in disputed milestone payments, while 3D Medicines says it will continue developing galinpepimut-S in Greater China.
On July 24, 2026, the sole arbitrator in the HKIAC arbitration dismissed SELLAS's claims against 3D Medicines.
SELLAS must pay approximately $1.0 million of 3D Medicines' legal fees and costs, as allocated by the arbitrator.
Unaudited cash and cash equivalents were $138.3 million as of June 30, 2026, subject to financial closing procedures.
$191.5 million in potential future milestone payments remained under the license as of March 31, 2026, including the $13.0 million in dispute.
LiqTech International received a Nasdaq notice on July 21, 2026, saying its common stock has not met the $1 minimum bid price for 30 consecutive business days. The stock continues to trade on the Nasdaq Capital Market under LIQT, and the company has until January 19, 2027 to regain compliance, with a possible second 180-day period, or face a delisting determination.
Nasdaq notice received July 21, 2026 under Listing Rule 5550(a)(2) for closing bid below $1.00 over 30 consecutive business days
Initial compliance period of 180 calendar days, ending January 19, 2027
To regain compliance, closing bid must be at least $1.00 for ten consecutive business days before January 19, 2027
Company may be eligible for a second 180-day period if it meets other listing standards and gives written notice; the company is considering its options
Odyssey Marine Exploration received a Nasdaq notice on July 21, 2026 that its stock failed to meet the $1.00 minimum bid price for 30 consecutive business days. The company has until January 19, 2027 to regain compliance, and the notice has no immediate effect on its listing. Shareholders should note that the company expects a previously approved reverse stock split to help it regain compliance before its pending merger with American Ocean Minerals Corporation takes effect.
Nasdaq notice dated July 21, 2026 cites failure to meet the $1.00 minimum bid price for 30 consecutive business days
Compliance period runs 180 calendar days, ending January 19, 2027; compliance requires a closing bid of at least $1.00 for ten consecutive business days
Stockholders approved a reverse stock split at a ratio between 1-for-20 and 1-for-25 on June 1, 2026
The company expects the reverse split to restore compliance before the merger with American Ocean Minerals Corporation takes effect
Versus Systems said it believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement, following a $1.7 million share sale to ASPIS Cyber Technologies and $1,485,000 of license revenue recognized in the quarter ended June 30, 2026. The compliance view rests on an unaudited pro forma balance sheet, and Nasdaq says it will keep monitoring and may delist the company if compliance is not shown at its next periodic report.
Company sold 1,310,969 shares of common stock to ASPIS Cyber Technologies on June 26, 2026, for $1,700,000.
Pro forma stockholders' equity was $3,403,606 as of June 30, 2026, against a $2,500,000 minimum; the balance sheet is unaudited.
ASPIS license fee is $165,000 per month through at least January 31, 2027; the entire $1,485,000 transaction price was recognized as revenue in the quarter ended June 30, 2026.
Nasdaq issued a deficiency letter on April 29, 2026, and may delist the company if compliance is not evidenced at its next periodic report.
BETA Technologies received notice on July 14, 2026 that the Defense Counterintelligence and Security Agency ended the Security Control Agreement dated June 15, 2025, which had mitigated foreign ownership and influence concerns tied to QIA Industrials Holding. DCSA determined the agreement was no longer necessary because QIA no longer has a seat on the Company's Board of Directors.
Security Control Agreement dated June 15, 2025 terminated, per DCSA notice received July 14, 2026
Agreement parties: QIA Industrials Holding, LLC, BETA Technologies, and the U.S. Department of Defense
Reason given: QIA no longer has board representation at the Company
Monopar Therapeutics said it has begun a rolling submission of a New Drug Application to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease, and has submitted its first completed sections. The filing is a regulatory milestone; approval is not assured, and the company says the drug could receive a pediatric Priority Review Voucher if approved.
Monopar has initiated a rolling NDA submission for ALXN1840 with the FDA and has submitted the first completed sections.
The FDA authorized the rolling submission, which lets completed sections be reviewed while remaining sections are finalized.
ALXN1840 received Rare Pediatric Disease designation from the FDA in June 2026, which could allow a pediatric Priority Review Voucher at approval.
Nasdaq staff said ProCap Financial, Inc. now complies with its independent director and audit committee requirements, and the matter is closed. The company had received a deficiency letter on January 26, 2026, and regained compliance after adding Benjamin Buchanan to its board and audit committee. The filing lists the registrant as ProCap Financial, Inc., not Silvia, Inc. as the request described, so the name should be checked against the ticker.
Nasdaq deficiency letter received January 26, 2026, citing independent director and audit committee rules (Listing Rules 5605(c)(2)(A) and 5605(b)(1))
Benjamin Buchanan appointed to the board and audit committee, disclosed in an 8-K filed July 16, 2026
On July 21, 2026, Nasdaq staff determined the company complies with the rules and closed the matter
On July 20, 2026, the U.S. District Court for the District of New Jersey dismissed with prejudice all claims and counterclaims in the long-running patent litigation between Miami International Holdings and Nasdaq. The parties have resolved all claims against each other, and the company states it can operate its business without a license or consent from Nasdaq on the matters Nasdaq asserted.
Court order of dismissal with prejudice entered July 20, 2026
Litigation began September 1, 2017, when Nasdaq filed suit against the company
In 2019, the PTAB invalidated six patents Nasdaq asserted against the company
Filing does not disclose any settlement payment or financial terms
CN Healthy Food Tech Group Corp. received a Nasdaq letter dated July 16, 2026 stating that Nasdaq staff has determined to delist its common stock and warrants. The company intends to request a hearing before a Nasdaq Panel by the July 23, 2026 deadline, which would stay any suspension pending the Panel's decision, but a trading halt currently in effect remains in place.
Nasdaq staff letter received July 16, 2026; determination based on Listing Rule 5101 and alleged violations of Rules 5205(e) and 5250(a)(1)
Company plans to request an appeal before a Nasdaq hearings panel by July 23, 2026
Trading halt currently in effect remains in place regardless of appeal; no assurance shares will resume trading or remain listed
Filing states the determination arises from a September 30, 2025 8-K regarding review by the China Securities Regulatory Commission
Origin Investment Corp I received a Nasdaq letter on July 15, 2026, saying it had not met the audit committee composition requirement as of July 2, 2026. On July 13, 2026, the board appointed Daniel Alef to the audit committee, and Nasdaq staff determined the company now complies and considers the matter closed. The issue does not appear to affect the company's listing status, though the filing does not report any financial figures.
Nasdaq letter dated July 15, 2026 cited audit committee composition rule 5605(c)(2)
Company lacked a third independent audit committee member as of July 2, 2026
Daniel Alef appointed to the Audit Committee effective July 13, 2026
Nasdaq staff determined the company is compliant and the matter is closed
SES AI Corp received a notice from the New York Stock Exchange on July 17, 2026, stating its Class A common stock fell below the $1.00 minimum average closing price over 30 consecutive trading days. The notice does not trigger immediate delisting, and the company has six months to regain compliance and says it intends to respond to the NYSE within 10 business days.
NYSE notice received July 17, 2026 under Section 802.01C of the NYSE Listed Company Manual
Company has six months from receipt of the notice to regain compliance by meeting a $1.00 closing and 30-day average price test
Class A common stock continues to trade on the NYSE during the cure period
Company may consider alternatives, including a reverse stock split that would require a stockholder vote
A federal court in Northern California granted C3.ai's motion to dismiss the securities class action against the company and certain officers on July 14, 2026, dismissing every cause of action. The ruling removes the claims in this case, though the filing does not describe any financial terms or whether the plaintiffs may appeal.
Complaint filed August 22, 2025, in the U.S. District Court for the Northern District of California (No. 3:25-cv-07129-TLT)
On July 14, 2026, the Court granted defendants' motion to dismiss the complaint in its entirety
The Court dismissed every cause of action in the complaint
The filing gives no dollar amount for damages, settlement, or legal costs
Actuate Therapeutics received a Nasdaq notice that its Market Value of Listed Securities fell below the $50 million minimum for continued listing on the Nasdaq Global Market from June 1, 2026 to July 14, 2026. The common stock continues to trade under the symbol ACTU, and the company has until January 11, 2027 to regain compliance, which could lead to delisting proceedings if it does not.
Nasdaq notice dated July 15, 2026 cites a market value of listed securities below the $50 million minimum for the period June 1, 2026 to July 14, 2026.
The common stock continues to trade on the Nasdaq Global Market under ACTU, as the notice has no immediate effect on listing.
Compliance Date is January 11, 2027; regaining compliance requires closing at $50 million or more for at least ten consecutive business days.
If compliance is not regained, Nasdaq will issue a delisting notice, which the company may appeal, or the company may consider transfer to the Nasdaq Capital Market.
The Sponsor, Grayscale Investments Sponsors, LLC, intends to enter into a Third Amended and Restated Declaration of Trust and Trust Agreement on or around August 7, 2026, to start regular cash distributions of net staking reward proceeds to shareholders. The Sponsor says the change is not materially adverse to shareholders and conforms the trust to IRS Revenue Procedure 2025-31, but it gave 20 days' prior notice, and distribution amounts will depend on staking rewards actually received.
Trust would reduce staking consideration to cash no less often than quarterly and distribute net proceeds to shareholders.
Distribution amounts depend on staking consideration actually received and cannot be predicted with certainty.
Sponsor gave shareholders 20 days' prior notice; execution is anticipated on or around August 7, 2026.
Filing includes updated tax consequences and supplemental risk factors as Exhibits 99.1 and 99.2; shareholders are advised to consult tax advisers.
The sponsor, Grayscale Investments Sponsors, LLC, intends to enter into a Fourth Amended and Restated Declaration of Trust on or around August 7, 2026, with 20 days' prior notice to shareholders. The amendment would require the trust to convert staking consideration to cash at least quarterly and distribute the net proceeds to shareholders, with amounts depending on staking rewards actually received. The filing states the sponsor considers the change not materially adverse to shareholders and tied to IRS Revenue Procedure 2025-31.
Proposed amendment intended for execution on or around August 7, 2026
Trust would reduce staking consideration to cash no less often than quarterly and distribute net proceeds to shareholders
Distribution amounts depend on staking consideration received and cannot be predicted with certainty
Shareholders advised to consult tax advisors; supplemental tax and risk disclosures filed as Exhibits 99.1 and 99.2
Aldeyra received minutes from a June 10, 2026 Type A meeting with the FDA about potential resubmission of the New Drug Application for reproxalap, a treatment for dry eye disease. The company has asked the FDA for a clarification of the minutes and plans to request a Type D meeting to discuss resubmission, which is expected by the end of the third quarter of 2026.
Type A meeting with the FDA held June 10, 2026; minutes received July 14, 2026
Clarification of the minutes requested from the FDA on July 15, 2026
Type D meeting on NDA resubmission expected by end of third quarter 2026
Marwynn Holdings, Inc. disclosed that Nasdaq notified it on July 10, 2026, that it had regained compliance with the $1.00 minimum bid price requirement for continued listing. The company had received a deficiency notice on January 29, 2026, and had until July 28, 2026 to regain compliance. The filing shows the stock closed at or above $1.00 for 10 consecutive business days, which removes the risk of delisting on this issue.
Nasdaq deficiency notice received January 29, 2026, for bid price below $1.00 for 30 consecutive business days
Nasdaq letter dated July 10, 2026, confirmed compliance with Listing Rule 5550(a)(2)
Closing bid price at or above $1.00 for 10 consecutive business days, June 25 to July 9, 2026
Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 is not approved by the FDA, and the filing contains no financial results.
FDA accepted the New Drug Application for AXS-12 (reboxetine) for cataplexy in narcolepsy for filing
PDUFA target action date set for May 1, 2027
FDA does not currently plan to hold an advisory committee meeting
AXS-12 has FDA Orphan Drug Designation for the treatment of narcolepsy
SemiLEDs disclosed that Nasdaq had notified it on January 30, 2026 that its stockholders' equity fell below the $2.5 million minimum, and that Nasdaq accepted its compliance plan with an extension of up to 180 calendar days. The company now believes it has regained compliance, based on stockholders' equity of $3.1 million as of May 31, 2026, but Nasdaq will keep monitoring and could start delisting if the next periodic report does not show compliance.
Nasdaq notice dated January 30, 2026 cited stockholders' equity below the $2.5 million minimum under Listing Rule 5550(b)(1)
Nasdaq accepted the company's plan and granted an extension of up to 180 calendar days from January 30, 2026
Total stockholders' equity was $3.1 million as of May 31, 2026, per the Form 10-Q
Company believes it has regained compliance; Nasdaq will monitor compliance in the next periodic report
SBC Medical received a Nasdaq notice that it no longer meets independent director and audit committee rules after Mike Sayama chose not to seek re-election. Stockholders also approved charter amendments and the board adopted amended bylaws, including a majority-vote resignation policy for uncontested director elections. The company says the notice has no immediate effect on its listing, but it must restore compliance within the cure period.
Nasdaq notice received July 10, 2026; board has four members, two of them independent, and the audit committee has two independent directors
Cure period ends at the earlier of the next annual meeting or July 9, 2027, or January 5, 2027 if the next annual meeting is held before that date
Restated charter effective July 9, 2026; amended and restated bylaws adopted July 8, 2026
Stockholders elected four directors and ratified MaloneBailey, LLP as auditor for fiscal 2026 with 93,954,650 votes for
Inno Holdings disclosed that a Magistrate Judge in the U.S. District Court for the Southern District of Texas issued a Memorandum and Recommendation on July 10, 2026 stating that "there is no TRO in place." The temporary restraining order entered June 25, 2026 against the company is therefore described as no longer in place. The filing contains no financial figures, so its direct financial effect on shareholders is not stated.
Temporary restraining order entered by the Southern District of Texas on June 25, 2026
Magistrate Judge issued a Memorandum and Recommendation on July 10, 2026 stating there is no TRO in place
Filing signed by CEO Ding Wei on July 13, 2026 and includes only Exhibit 104 (cover page XBRL data)
ENDRA Life Sciences received a Nasdaq notice on July 8, 2026 that it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, after the Staff flagged a shortfall in its 2025 annual report. The company will be under a Discretionary Panel Monitor for one year from July 1, 2026, and if it falls out of compliance again within that period, it could face delisting without a cure period.
Nasdaq Staff letter dated April 20, 2026 cited stockholders' equity below the $2,500,000 minimum, based on the 2025 Form 10-K
Company requested a Nasdaq Hearing Panel hearing on April 27, 2026; hearing held May 28, 2026
On July 8, 2026 Nasdaq notified the company it regained compliance
One-year Discretionary Panel Monitor runs from July 1, 2026; a new deficiency could lead to a Delist Determination Letter and possible delisting
An arbitration tribunal issued a final award on July 6, 2026, declaring that Prime Medicine's PM647 candidate for Alpha-1 Antitrypsin Deficiency is within the agreement's Field and that the company did not breach its 2019 agreement with Beam Therapeutics. The tribunal denied Beam's requests for damages and injunctive relief and denied the remaining claims by both parties. The ruling removes a breach claim tied to a key development candidate, though the filing gives no financial figures.
Final Award received July 6, 2026 from the arbitration tribunal in proceedings with Beam Therapeutics
Tribunal declared PM647, targeting Alpha-1 Antitrypsin Deficiency, is within the agreement's Field
Tribunal denied Beam's requests for damages and injunctive relief and denied remaining claims by both parties
CISO Global received a second 180-day Nasdaq compliance period, running to December 28, 2026, to regain the $1.00 minimum bid price for its common stock. The company's shares will keep trading on The Nasdaq Capital Market in the meantime, but if the bid price does not stay at or above $1.00 for ten consecutive business days, Nasdaq could begin delisting the stock.
Bid price closed below $1.00 for 30 consecutive business days, prompting a Nasdaq notice dated December 30, 2025.
The original compliance deadline was June 29, 2026; Nasdaq extended it to December 28, 2026 on June 30, 2026.
Regaining compliance requires a closing bid price of at least $1.00 for ten consecutive business days; a reverse stock split may be used if necessary.
If compliance is not shown by December 28, 2026, Nasdaq staff will issue a delisting notice, and the company may appeal to a Hearings Panel.
On July 1, 2026, Network-1's subsidiary HFT Solutions dismissed without prejudice its patent infringement lawsuit against Jump Trading in federal court in Northern Illinois. The company says it may revisit IP-related claims against Jump and others later, depending on future developments.
Dismissal date: July 1, 2026
Lawsuit filed by HFT Solutions, LLC, a Network-1 subsidiary, against Jump Trading, LLC
Case was pending in the U.S. District Court for the Northern District of Illinois and involved patents in Network-1's HFT patent portfolio
Network-1 may revisit IP claims against Jump and others in the future
AI Financial Corporation received a Nasdaq notice on July 1, 2026, that its common stock has traded below the $1.00 minimum closing bid price for 30 consecutive business days. The notice has no immediate effect on trading, and the stock continues to trade on the Nasdaq Capital Market as AIFC, but the company must regain compliance or face possible delisting.
Nasdaq notified the company on July 1, 2026; June 30, 2026 was the 30th consecutive day below $1.00
Compliance period runs 180 calendar days, until December 28, 2026, requiring at least 10 consecutive business days at or above $1.00
If not compliant by then, Nasdaq may grant a second 180-day period; otherwise delisting determination with right to appeal to a Hearings Panel
Company may consider options including a reverse stock split
HeartBeam, Inc. received a Nasdaq notice on June 30, 2026, saying its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The notice has no immediate effect on the listing, but the company must regain compliance by December 28, 2026, or face possible delisting.
Nasdaq letter dated June 30, 2026 cites non-compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2)
Company has a 180 calendar day compliance period, until December 28, 2026, to show a closing bid of at least $1.00 for ten consecutive business days
A second 180-day period may be available if the company meets market value and other initial listing standards, and the company says it cannot assure it will regain compliance
Navient disclosed a material cybersecurity incident in which a ransomware attack on a third-party law firm led to unauthorized access to Company-related borrower data, including names, dates of birth, addresses and Social Security numbers. The company says its own systems were not accessed and operations were not disrupted, and it does not believe the incident has had or is reasonably likely to have a material impact on its financial condition or results.
Company became aware of the incident on June 8, 2026, and determined it material on June 29, 2026
Exposed data includes borrower names, dates of birth, addresses and Social Security numbers
Incident was limited to the law firm's environment; no evidence of access to Navient systems and no operational disruption
Notifications to affected individuals and regulators are underway; law enforcement has been notified
AdaptHealth said a threat actor gained unauthorized access to certain cloud-based business applications, including patient management and document storage systems, and exfiltrated some data. The company determined on June 27, 2026 that the incident is material, and said it has contained the threat and that operations and patient service have not been materially affected. The full financial impact, data scope and volume remain undetermined, and the company says cybersecurity insurance may cover some losses.
Threat actor contacted the company on June 15, 2026, claiming to have obtained data from its systems
Affected data includes insurance billing passwords and certain patient personally identifiable and protected health information
Company does not collect Social Security numbers or store financial account or payment card data in the affected systems
Company says it cannot yet determine the full financial impact and will amend the filing as information becomes available
On July 1, 2026, the Centers for Medicare & Medicaid Services withdrew billing and fee schedule changes that followed the FDA's April 16, 2026 reclassification of non-invasive bone growth stimulators. Orthofix now expects average Medicare reimbursement for the affected codes to return to the rates in effect before May 18, 2026. The filing gives no dollar figures for the expected impact.
FDA final order on April 16, 2026 reclassified non-invasive bone growth stimulators from Class III to Class II devices.
CMS changes to billing and Medicare fee schedule treatment applied to HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026.
On July 1, 2026, CMS withdrew those changes and directed that devices furnished on or after May 18, 2026 be paid as before the reclassification.
Orthofix expects average Medicare reimbursement for these codes to return to pre-May 18, 2026 rates; no dollar amounts were disclosed.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.